1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Nasdaq
  6. News
  7. Summary
    NDAQ   US6311031081

NASDAQ

(NDAQ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022

01/14/2022 | 07:07am EDT

EASTWOOD, Australia, Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX, ASX: BNO), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, will ring the Nasdaq Closing Bell remotely from around the globe.

Dr Errol De Souza, Executive Chairman, will ring the Closing Bell alongside the Company's team in a virtual bell ringing ceremony.

When:
FRIDAY, JANUARY 14, 2021 – 3:45 p.m. to 4:00 p.m. ET 

Webcast:
A live stream of the Nasdaq Closing Bell will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony  

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/nasdaq

For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to https://www.nasdaq.com/marketsite/bell-ringing-ceremony  and click on the market close of your choice.

FOR FURTHER INFORMATION PLEASE CONTACT:

General:

Ms Suzanne Irwin

Company Secretary

+61 8 8150 7400

CoSec@bionomics.com.au 

Investor Relations:

Mr. Connor Bernstein

Vice President, Strategy and Corporate Development

+1 (831) 246 3642

cbernstein@bionomics.com.au

About Bionomics Limited:
Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.  To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Bionomics1, or at www.bionomics.com.au.

About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Cision
View original content:https://www.prnewswire.com/news-releases/bionomics-limited-nasdaq-bnox-asx-bno-to-ring-the-nasdaq-stock-market-closing-bell-on-friday-january-14-2022-301461190.html

SOURCE Bionomics Limited


ę PRNewswire 2022
All news about NASDAQ
05/17Delisting of Securities of GWG Holdings, Inc. fromáTheáNasdaq Stock Market
AQ
05/17Nasdaq Launches Digital Education Program to Increase Knowledge of Equity Derivatives
GL
05/17Nasdaq Launches Digital Education Program to Increase Knowledge of Equity Derivatives
AQ
05/12Brazil's Banco Inter shareholders okay switch to Nasdaq
RE
05/12Nasdaq Announces 2022 Annual Meeting of Shareholders
AQ
05/11Special Report-How Wall Street banks made a killing on SPAC craze
RE
05/10Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Sett..
AQ
05/04NASDAQ, INC. Management's Discussion and Analysis of Financial Condition and Results O..
AQ
05/04Just Eat Takeaway faces shareholder backlash over dealmaking
RE
05/03Nasdaq April 2022 Volumes
AQ
More news
Analyst Recommendations on NASDAQ
More recommendations